Rationale and design of a randomized study to assess the efficacy and safety of evolocumab in patients with diabetes and dyslipidemia: The BERSON clinical trial

被引:15
作者
Lorenzatti, Alberto J. [1 ]
Eliaschewitz, Freddy G. [2 ]
Chen, Yundai [3 ]
Fialkow, Jonathan [4 ]
Lu, Juming [5 ]
Baass, Alexis [6 ]
Monsalvo, Maria Laura [7 ]
Hsu, Hui-Chun [7 ]
Somaratne, Ransi [7 ]
Ge, Junbo [8 ]
机构
[1] Inst Med DAMIC Fdn Rusculleda, Ave Colon 2057 X5003DCE, Cordoba, Argentina
[2] Ctr Pesquisas Clin, Sao Paulo, Brazil
[3] Chinese People Liberat Army Gen Hosp, Dept Cardiol, Beijing, Peoples R China
[4] Cardiovasc Ctr South Florida, Miami, FL USA
[5] Chinese People Liberat Army Gen Hosp, Dept Endocrinol, Beijing, Peoples R China
[6] Royal Victoria Hosp, Dept Med, Quebec City, PQ, Canada
[7] Amgen Inc, Clin Dev, Thousand Oaks, CA 91320 USA
[8] Fudan Univ, Zhongshan Hosp, Shanghai Inst Cardiovasc Dis, Dept Cardiol, Shanghai, Peoples R China
关键词
diabetes; diabetic dyslipidemia; dyslipidemia; hypercholesterolemia; monoclonal antibody; PCSK9; inhibitor; LIPID-LOWERING EFFICACY; CORONARY-HEART-DISEASE; AMG; 145; POOLED ANALYSIS; STATIN THERAPY; CARDIOVASCULAR-DISEASE; INHIBITOR EVOLOCUMAB; DOUBLE-BLIND; PCSK9; HYPERCHOLESTEROLEMIA;
D O I
10.1002/clc.23018
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Type 2 diabetes mellitus (T2DM) is a major independent risk factor for cardiovascular disease, and diabetic dyslipidemia is a major contributor to cardiovascular risk in these patients. Here we report the rationale and design of a phase 3, double-blind study specifically designed to evaluate the lipid-lowering efficacy of the proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor evolocumab in patients with T2DM and hyperlipidemia or mixed dyslipidemia who are on background statin therapy. In the BERSON (evolocumaB Efficacy for LDL-C Reduction in subjectS with T2DM On background statiN) trial, patients with T2DM, a screening low-density lipoprotein cholesterol (LDL-C) level of >= 2.6 mmol/L (>= 100 mg/dL) or >= 3.4 mmol/L (>= 130 mg/dL), and with or without statin treatment at screening, respectively, were enrolled and started on atorvastatin 20 mg/day for a lipid stabilization period of at least 4 weeks. Then, patients were randomly assigned in a 2:2:1:1 ratio to receive atorvastatin 20 mg once daily plus either evolocumab 140 mg every 2 weeks (Q2W), evolocumab 420 mg every month (QM), placebo Q2W, or placebo QM. The co-primary outcome measures were the percentage change from baseline in LDL-C at week 12 and the percentage change from baseline in LDL-C at the mean of weeks 10 and 12. The BERSON trial has completed enrollment. The study completed in the first half of 2018, and will provide information on the efficacy and safety of evolocumab in patients with T2DM and dyslipidemia.
引用
收藏
页码:1117 / 1122
页数:6
相关论文
共 50 条
  • [21] Efficacy and Safety of Imarikiren in Patients with Type 2 Diabetes and Microalbuminuria A Randomized, Controlled Trial
    Ito, Sadayoshi
    Kagawa, Tomoya
    Saiki, Takuya
    Shimizu, Kohei
    Kuroda, Shingo
    Sano, Yuhei
    Umeda, Yuusuke
    CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2019, 14 (03): : 354 - 363
  • [22] The efficacy and safety of vildagliptin in patients with type 2 diabetes: a meta-analysis of randomized clinical trials
    Cai, L.
    Cai, Y.
    Lu, Z. J.
    Zhang, Y.
    Liu, P.
    JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS, 2012, 37 (04) : 386 - 398
  • [23] Efficacy and Safety of Canagliflozin Used in Conjunction with Sulfonylurea in Patients with Type 2 Diabetes Mellitus: A Randomized, Controlled Trial
    Fulcher, Greg
    Matthews, David R.
    Perkovic, Vlado
    de Zeeuw, Dick
    Mahaffey, Kenneth W.
    Weiss, Robert
    Rosenstock, Julio
    Capuano, George
    Desai, Mehul
    Shaw, Wayne
    Vercruysse, Frank
    Meininger, Gary
    Neal, Bruce
    DIABETES THERAPY, 2015, 6 (03) : 289 - 302
  • [24] Evolocumab treatment in patients with HIV and hypercholesterolemia/mixed dyslipidemia: BEIJERINCK study design and baseline characteristics
    Boccara, Franck
    Kumar, Princy
    Caramelli, Bruno
    Calmy, Alexandra
    Lopez, J. Antonio G.
    Bray, Sarah
    Cyrille, Marcoli
    Rosenson, Robert S.
    AMERICAN HEART JOURNAL, 2020, 220 : 203 - 212
  • [25] The efficacy and safety of berberine in combination with cinnamon supplementation in patients with type 2 diabetes: a randomized clinical trial
    Mansour, Asieh
    Sajjadi-Jazi, Sayed Mahmoud
    Gerami, Hadis
    Khorasanian, Atie Sadat
    Moalemzadeh, Behnam
    Karimi, Sara
    Afrakoti, Nima Mohamadi
    Mofid, Vahid
    Mohajeri-Tehrani, Mohammad Reza
    Hekmatdoost, Azita
    EUROPEAN JOURNAL OF NUTRITION, 2025, 64 (02)
  • [26] Efficacy and tolerability of two different formulations of atorvastatin in Korean patients with hypercholesterolemia: a multicenter, prospective, randomized clinical trial
    Lee, Ju-Hee
    Kim, Sang-Hyun
    Choi, Dong-Ju
    Tahk, Seung-Jea
    Yoon, Jung-Han
    Choi, Si Wan
    Hong, Taek-Jong
    Kim, Hyo-Soo
    DRUG DESIGN DEVELOPMENT AND THERAPY, 2017, 11 : 2277 - 2285
  • [27] Pilot clinical trial of macimorelin to assess safety and efficacy in patients with cancer cachexia
    Herodes, Megan
    Anderson, Lindsey J. J.
    Shober, Samuel
    Schur, Ellen A. A.
    Graf, Solomon A. A.
    Ammer, Nicola
    Salas, Ramiro
    Marcelli, Marco
    Garcia, Jose M. M.
    JOURNAL OF CACHEXIA SARCOPENIA AND MUSCLE, 2023, 14 (02) : 835 - 846
  • [28] Efficacy and Safety of Sitagliptin in Patients With Type 2 Diabetes and ESRD Receiving Dialysis: A 54-Week Randomized Trial
    Ferreira, Juan C. Arjona
    Corry, Dalila
    Mogensen, Carl E.
    Sloan, Lance
    Xu, Lei
    Golm, Gregory T.
    Gonzalez, Edward J.
    Davies, Michael J.
    Kaufman, Keith D.
    Goldstein, Barry J.
    AMERICAN JOURNAL OF KIDNEY DISEASES, 2013, 61 (04) : 579 - 587
  • [29] A cluster randomized controlled Trial to Evaluate an Ambulatory primary care Management program for patients with dyslipidemia: the TEAM study
    Villeneuve, Julie
    Genest, Jacques
    Blais, Lucie
    Vanier, Marie-Claude
    Lamarre, Diane
    Fredette, Marc
    Lussier, Marie-Therese
    Perreault, Sylvie
    Hudon, Eveline
    Berbiche, Djamal
    Lalonde, Lyne
    CANADIAN MEDICAL ASSOCIATION JOURNAL, 2010, 182 (05) : 447 - 455
  • [30] A randomized clinical trial of the efficacy and safety of sitagliptin compared with dapagliflozin in patients with type 2 diabetes mellitus and mild renal insufficiency: The CompoSIT-R study
    Scott, Russell
    Morgan, Jerry
    Zimmer, Zachary
    Lam, Raymond L. H.
    O'Neill, Edward A.
    Kaufman, Keith D.
    Engel, Samuel S.
    Raji, Annaswamy
    DIABETES OBESITY & METABOLISM, 2018, 20 (12) : 2876 - 2884